Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells

Androgen deprivation is the primary therapy for recurrent prostate cancer, and agents targeting the androgen receptor (AR) pathway continue to be developed. Because androgen-deprivation therapy (ADT) has immmunostimulatory effects as well as direct antitumor effects, AR-targeted therapies have been...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunol Res
Main Authors: Olson, Brian M., Gamat, Melissa, Seliski, Joseph, Sawicki, Thomas, Jeffery, Justin, Ellis, Leigh, Drake, Charles G., Weichert, Jamey, McNeel, Douglas G.
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873299/
https://ncbi.nlm.nih.gov/pubmed/29051161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-16-0390
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items